AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22951317
Drug: Citicoline 1000mg
RxNorm normalized name: citicoline 1000 MG
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 1000mg (reference control release tablet)
Trial: 18039433
Drug: Oxycodone (prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (prolonged-release form)
Trial: 16462818
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Orlistat three times a day
Trial: 10735889
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine treatment (n = 250)
Trial: 10735889
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (n = 112)
Trial: 15251156
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine treatment
Trial: 10735889
Drug: Nodal status,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nodal status, estrogen receptor (ER) status, tumor size
Trial: 8774551
Drug: 6 methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 methylprednisolone (6MP) i.v. for 3 days at 5 mg/kg/d and for an additional 3 days at 2.5 mg/kg/d followed by po prednisone (1 mg/kg/d)
Trial: 8774551
Drug: po prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: po prednisone (1 mg/kg/d)
Trial: 1635824
Drug: Inspiratory flow-resistive
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow-resistive load training (75 cm H2O.L-1.s in week 1 and 90 cm H2O.L-1.s in week 2)
Trial: 6708393
Drug: Digitalis and
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis and diuretics (group III)
Trial: 6708393
Drug: Digitalis and
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis and K+-saving diuretics (group IV)
Trial: 6708393
Drug: Digitalis and
RxNorm normalized name: Digitalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis and K+-losing diuretics (group V)
Trial: 29419917
Drug: Placebo/Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/Metformin
Trial: 25012934
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 initial monthly doses (2q8)
Trial: 22528165
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg (Group AA)
Trial: 22528165
Drug: Atorvastatin on
RxNorm normalized name: Atorvastatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin on the day of surgery and for seven days post surgery (Group PA)
Trial: 18482525
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (intravenous insulin with target glycemia levels of 80-110 mg/dl)
Trial: 18482525
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (subcutaneous insulin only when glycemia was 160 mg/dl)
Trial: 18482525
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test after 4 weeks
Trial: 15683372
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg) followed by misoprostol (0.8 mg)
Trial: 12789384
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and tolerance)
Trial: 1810359
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg for 1 week, then 300 mg)
Trial: 1810359
Drug: Mianserin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (60 mg for 1 week, then 180 mg)
Trial: 1090417
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate ointment
Trial: 9118626
Drug: Ointment base
RxNorm normalized name: Ointment base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment base (control)
Trial: 31740368
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg twice daily for 3 months
Trial: 26807956
Drug: Animal-assisted activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted activities (AAA) with a dog, 30-min sessions twice weekly for 12 weeks
Trial: 27155968
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with treatment as usual
Trial: 25108482
Drug: Avoidance combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoidance combined with cognitive behavior therapy (Avoid + CBT)
Trial: 19838130
Drug: vicriviroc (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vicriviroc (5, 10, or 15 mg/day)
Trial: 16284465
Drug: Dextrin sulphate
RxNorm normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrin sulphate (DS) gel twice daily
Trial: 16284465
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel twice daily
Trial: 16284465
Drug: Dextrin sulphate
RxNorm normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrin sulphate (DS) gel pre-sex
Trial: 16284465
Drug: Dextrin sulphate
RxNorm normalized name: Dextrin sulphate
DrugBank: Dextrin 2-sulfate (DB06496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrin sulphate (DS) gel
Trial: 12365857
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg orally twice daily (n=19)
Trial: 12365857
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg orally thrice daily (n=20)
Trial: 9798811
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education and inhaled steroids usage
Trial: 7806712
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for depression over 12 weeks
Trial: 2791812
Drug: Intravenous cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisapride (8.0 mg)
Trial: 2791812
Drug: Oral cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cisapride (10.0 mg)
Trial: 2791812
Drug: Oral cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cisapride (5.0 mg)
Trial: 2791812
Drug: Intravenous cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisapride followed by intravenous atropine
Trial: 1130311
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 supplementation (0.8, 2.0, or 20.0 mg of pyridoxine hydrochloride)
Trial: 28376149
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin therapy (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Trial: 12952833
Drug: Low-dose paclitaxel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose paclitaxel (1.28 microg/mm2)
Trial: 12952833
Drug: High-dose paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose paclitaxel (3.10 microg/mm2)
Trial: 8643884
Drug: Randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatment (734 patients, 35% of total)
Trial: 8643884
Drug: Non-randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomized treatment (1350 patients, 65% of total)
Trial: 3908262
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg mane
Trial: 22767005
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (1 L the night before and 1 L on the day of the exam) with bisacodyl 10 mg
Trial: 22767005
Drug: Mannitol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (1 L of a 10% mannitol solution on the day of the exam) with bisacodyl 20 mg
Trial: 20666948
Drug: Estrogen +
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen + progestin therapy (HT)
Trial: 16181878
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose AF0144 (1.8 g/kg)
Trial: 16181878
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose AF0144 (2.7 g/kg)
Trial: 7774741
Drug: Syntometrine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntometrine 1 ml (oxytocin 5 units + ergometrine 0.5 mg)
Trial: 2191071
Drug: Nopharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nopharmacological treatment group
Trial: 31066315
Drug: Traditional mirror
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional mirror therapy (4 weeks)
Trial: 31066315
Drug: Self-delivered mirror
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-delivered mirror therapy (6 weeks)
Trial: 26285020
Drug: Caffeine-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-containing supplement (CAF)
Trial: 24343092
Drug: ARV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV therapy longer than 2 years
Trial: 17240224
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg orally, 4 x daily for 3 days)
Trial: 17240224
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg orally, 4 x daily for 3 days)
Trial: 7957450
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of theophylline
Trial: 3303983
Drug: Steam inhalation
RxNorm normalized name: Leader Hot Steam Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam inhalation (two 20-minute sessions of inhaling saturated, hot air at 42-44 degrees C)
Trial: 29936590
Drug: Epinephrine (0.2-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.2-0.4 μg/kg/min)
Trial: 29936590
Drug: Dopamine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (10-20 μg/kg/min)
Trial: 25196061
Drug: 90 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 μg PEG‐IFNα‐2a weekly
Trial: 25196061
Drug: 135 μg
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 135 μg PEG‐IFNα‐2a weekly
Trial: 25196061
Drug: PEG‐IFNα‐2a treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα‐2a treatment with HCV RNA negativation at 4 weeks
Trial: 25196061
Drug: PEG‐IFNα‐2a treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα‐2a treatment with HCV RNA positivity at 24 weeks
Trial: 25196061
Drug: Treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment discontinuation due to adverse events
Trial: 29420335
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT)
Trial: 22843377
Drug: Primary alternating
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary alternating CRT or concurrent CRT (non-ICT)
Trial: 20016011
Drug: Iron-fortified milk
RxNorm normalized name: iron succinyl milk protein complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified milk (FM); Daily portion contained 5.28 mg Fe (ferrous gluconate) and 48 mg sodium ascorbate
Trial: 17573492
Drug: Good compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good compliance to CPAP treatment (n = 20)
Trial: 17573492
Drug: Poor compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Poor compliance to CPAP treatment (n = 19)
Trial: 17573492
Drug: Refusal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refusal of CPAP treatment (n = 14)
Trial: 16213352
Drug: Low-dose histidine-tryptophan-ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose histidine-tryptophan-ketoglutarate (HTK) solution
Trial: 9557112
Drug: Immunohistochemical analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical analysis for oestrogen and progesterone receptors
Trial: 3920695
Drug: Desipramine (DMI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI, 150 mg/day for 28 days)
Trial: 3920695
Drug: Amitriptyline (AT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AT, dosage not specified for 28 days)
Trial: 3069519
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (10-40 mg/day)
Trial: 3069519
Drug: Paracetamol (1000-4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1000-4000 mg/day)/codeine (60-240 mg/day)
Trial: 30476217
Drug: Regular diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular diet mixed with a commercial synbiotic product at 1.0 g/kg (1.0X)
Trial: 30476217
Drug: Regular diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular diet mixed with a commercial synbiotic product at 0.5 g/kg (0.5X)
Trial: 23437909
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose SST (250 μg bolus + continuous infusion of 250 μg/h)
Trial: 23437909
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose SST (500 μg bolus + continuous infusion of 250 μg/h)
Trial: 23437909
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose SST (250 μg bolus + continuous infusion of 500 μg/h)
Trial: 23437909
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo saline injection + placebo infusion)
Trial: 19894302
Drug: Cereton 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereton 1000 mg intramuscular for 15 days
Trial: 9050731
Drug: Diagnostic laparoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic laparoscopy without treatment
Trial: 9050731
Drug: Danazol 800
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 800 mg/day for 3 months after diagnostic laparoscopy
Trial: 3943883
Drug: Alpha-methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-methyldopa (500 mg oral dose)
Trial: 27470026
Drug: Atazanavir 200
RxNorm normalized name: atazanavir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 200 mg and ritonavir 100 mg (low dose)
Trial: 27470026
Drug: Atazanavir 300
RxNorm normalized name: atazanavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 300 mg and ritonavir 100 mg (standard dose)
Trial: 18953082
Drug: lisinopril/hydrochlorothiazide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril/hydrochlorothiazide with ibuprofen
Trial: 18953082
Drug: lisinopril/hydrochlorothiazide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril/hydrochlorothiazide with piroxicam
Trial: 18953082
Drug: lisinopril/hydrochlorothiazide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril/hydrochlorothiazide with acetaminophen
Trial: 18953082
Drug: lisinopril/hydrochlorothiazide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril/hydrochlorothiazide with ibuprofen or piroxicam (second exposition)
Trial: 18953082
Drug: amlodipine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine with ibuprofen or piroxicam
Trial: 15987289
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day
Trial: 15987289
Drug: 100 mg/week
RxNorm normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/week
Trial: 15987289
Drug: 400 mg/week
RxNorm normalized name: tovorafenib 400 mg/week (100 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/week
Trial: 8522380
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ceftazidime i.v. t.d.s.
Trial: 8522380
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg ceftazidime i.v. t.d.s.
Trial: 6111438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta-receptor blocker and diuretic (10 mg pindolol and 5 mg clopamide daily)
Trial: 6111438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta-receptor blocker, diuretic and sodium-preserving diuretic (10 mg timolol, 25 mg hydrochlorothiazide and 2.5 mg amiloride)
Trial: 28939629
Drug: Prolongation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolongation of adalimumab dosing interval to once every 3 weeks
Trial: 28939629
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of adalimumab dosing interval every other week
Trial: 26201083
Drug: Adolescent-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent-focused therapy
Trial: 22546131
Drug: Liposome bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome bupivacaine (LB) 66, 199, or 266 mg
Trial: 22546131
Drug: bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine HCl 75 mg
Trial: 20133204
Drug: Pulsed high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed high-dose dexamethasone
Trial: 20133204
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral prednisolone
Trial: 17397425
Drug: Multifactorial falls
RxNorm normalized name: Halls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial falls intervention (two in-home visits, recommendations, referrals, 11 monthly calls, balance exercise plan)
Trial: 15736248
Drug: Trapidil 200
RxNorm normalized name: trapidil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil 200 mg t.i.d. for 6 months
Trial: 11896096
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5-FU) chemotherapy at doses of 370 to 450 mg/m² for 5 consecutive days
Trial: 11896096
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5-FU) chemotherapy
Trial: 7659440
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (KET) 60 mg before induction (PRE group)
Trial: 7659440
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline followed by intravenous ketorolac (KET) 60 mg (POST group)
Trial: 7659440
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (KET) 60 mg (PRE group)
Trial: 2683424
Drug: HDL-rich Cohn-IV-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL-rich Cohn-IV-1 fractions infusion (100 ml every 2 weeks)
Trial: 2683424
Drug: Cholestyramine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine and a choleretic drug (permanent medication)
Trial: 25046539
Drug: Isoproterenol (ISO:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (ISO: 0.05 μg/kg per minute)
Trial: 21834938
Drug: PP 1420
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP 1420 (2, 4, and 8 mg)
Trial: 20507969
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (IMT) - 4 weeks, 30 breaths twice daily at approximately 50% of maximum inspiratory pressure (MIP)